Czech National Bank Increases Stock Position in Bristol-Myers Squibb (NYSE:BMY)

Czech National Bank boosted its position in Bristol-Myers Squibb (NYSE:BMY) by 0.4% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 358,018 shares of the biopharmaceutical company’s stock after acquiring an additional 1,583 shares during the period. Czech National Bank’s holdings in Bristol-Myers Squibb were worth $19,415,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Northwest Financial Advisors bought a new stake in Bristol-Myers Squibb in the 4th quarter worth $27,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Bristol-Myers Squibb in the 4th quarter worth $34,000. VisionPoint Advisory Group LLC boosted its stake in shares of Bristol-Myers Squibb by 300.5% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 553 shares in the last quarter. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $40,000. Finally, Wetzel Investment Advisors Inc. bought a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $40,000. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Stock Up 0.6 %

Bristol-Myers Squibb stock traded up $0.23 during trading hours on Thursday, hitting $41.05. The stock had a trading volume of 18,638,801 shares, compared to its average volume of 15,506,325. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The stock has a market capitalization of $83.20 billion, a P/E ratio of -13.24, a price-to-earnings-growth ratio of 13.82 and a beta of 0.43. Bristol-Myers Squibb has a 12-month low of $39.63 and a 12-month high of $66.38. The stock’s 50-day moving average price is $43.73 and its 200-day moving average price is $48.50.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. During the same period in the previous year, the company earned $2.05 earnings per share. The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. Equities research analysts anticipate that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be issued a dividend of $0.60 per share. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 5.85%. Bristol-Myers Squibb’s payout ratio is -77.42%.

Analysts Set New Price Targets

BMY has been the topic of a number of research reports. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Wells Fargo & Company lifted their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. BMO Capital Markets cut their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. Barclays cut their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. Finally, StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.